

Apolipoprotein E for Risk Assessment and Management of Cardiovascular Disease

Effective: February 1, 2019

Next Review: December 2019

Last Review: January 2019

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Apolipoprotein E (apo E) genotype has been associated with risk for coronary artery disease (CAD) and may affect responses to lipid-lowering medications. Genetic testing of apo E has been proposed for individual CAD risk assessment and to predict the response to statin therapy.

MEDICAL POLICY CRITERIA

Apolipoprotein E genetic testing is considered **investigational** for the risk assessment and management of cardiovascular disease.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

CROSS REFERENCES

1. [Measurement of Lipoprotein-Associated Phospholipase A2 \(Lp-PLA2\) in the Assessment of Cardiovascular Risk](#). Laboratory, No. 63

BACKGROUND

Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular disease. Low-density lipoproteins (LDL) have been identified as the major atherogenic lipoproteins and have long been identified by the National Cholesterol Education Project (NCEP) as the primary target of cholesterol-lowering therapy. LDL particles consist of a surface coat composed of phospholipids, free cholesterol, and apolipoproteins surrounding an inner lipid core composed of cholesterol ester and triglycerides. Traditional lipid risk factors such as LDL-cholesterol (LDL-C), while predictive on a population basis, are weaker markers of risk on an individual basis. Only a minority of subjects with elevated LDL and cholesterol levels will develop clinical disease, and up to 50% of cases of coronary artery disease (CAD) occur in subjects with ‘normal’ levels of total and LDL-C. Thus, there is considerable potential to improve the accuracy of current cardiovascular risk prediction models.

Apolipoprotein E (apo E) is the primary apolipoprotein found in very-low-density lipoproteins (VLDLs) and chylomicrons. Apo E is the primary binding protein for LDL receptors in the liver and is thought to play an important role in lipid metabolism. The apo E gene is polymorphic, consisting of three alleles (e2, e3, and e4) that code for three protein isoforms, known as E2, E3, and E4, which differ from one another by one amino acid. These molecules mediate lipid metabolism through their different interactions with the LDL receptors. The genotype of apo E alleles can be assessed by gene amplification techniques, or the apo E phenotype can be assessed by measuring plasma levels of apo E.

It has been proposed that various apo E genotypes are more atherogenic than others and that apo E measurement may provide information on risk of CAD above traditional risk factor measurement. It has also been proposed that the apo E genotype may be useful in the selection of specific components of lipid-lowering therapy such as drug selection. In the major lipid-lowering intervention trials, including trials of statin therapy, there is considerable variability in response to therapy that cannot be explained by factors such as compliance. Apo E genotype may be one factor that determines an individual’s degree of response to interventions such as statin therapy.

EVIDENCE SUMMARY

Human Genome Variation Society (HGVS) nomenclature^[1] is used to describe variants found in DNA and serves as an international standard. It is being implemented for genetic testing medical evidence review updates starting in 2017. According to this nomenclature, the term “variant” is used to describe a change in a DNA or protein sequence, replacing previously-used terms, such as “mutation.” Pathogenic variants are variants associated with disease, while benign variants are not. The majority of genetic changes have unknown effects on human health, and these are referred to as variants of uncertain significance.

A 2002 BlueCross BlueShield Association Technology Evaluation Center (TEC) Assessment^[2] summarized the steps necessary to determine utility of a novel cardiac risk factor. Three steps were required:

- Standardization of the measurement of the risk factor.
- Determination of its contribution to risk assessment. As a risk factor, it is important to determine whether the novel risk factor [...] independently contributes to risk assessment compared to established risk factors.

- Determination of how the novel risk assessment will be used in the management of the patient, compared to standard methods of assessing risk, and whether any subsequent changes in patient management result in an improvement in patient outcome.

Similarly, the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III; ATP III) noted that emerging risk factors should be evaluated against the following criteria in order to determine their clinical significance:^[3]

- Significant predictive power that is independent of other major risk factors
- A relatively high prevalence in the population (justifying routine measurement in risk assessment)
- Laboratory or clinical measurement must be widely available, well standardized, inexpensive, have accepted population reference values, and be relatively stable biologically
- Preferable, but not necessarily, modification of the risk factor in clinical trials will have shown reduction in risk.

The focus of the following literature appraisal is on evidence related to the clinical utility of testing or the ability of apo E testing to:

- Provide clinically relevant information beyond that provided by traditional lipid measures, and
- Improve health outcomes as a result of patient management decisions that would not otherwise have been made in the absence of apo E testing.

APO E AS A PREDICTOR OF CARDIOVASCULAR DISEASE

A large body of research has established a correlation between lipid levels and the underlying apo E genotype. Numerous studies have focused on the relationship between genotype and physiologic markers of atherosclerotic disease. A number of small- to medium-sized cross-sectional and case-control studies have correlated apo E with surrogate outcomes such as cholesterol levels, markers of inflammation, or carotid intima-media thickness.^[4-9] These studies have generally shown a relationship between apo E and these surrogate outcomes. For example, in population studies, the presence of an apo e2 allele was associated with the lowest cholesterol levels and the apo e4 allele was associated with the highest levels.^[10,11] Other studies have suggested that carriers of apo e4 are more likely to develop signs of atherosclerosis independent of total and LDL-cholesterol levels.^[12-15]

Some larger observational studies have correlated apo E genotype with clinical disease. For example, the Atherosclerosis Risk in Communities (ARIC) study followed 12,000 middle-aged individuals free of coronary artery disease (CAD) at baseline for 10 years.^[16] This study reported that the e3/2 genotype was associated with carotid artery atherosclerosis after controlling for other atherosclerotic risk factors. Volcik (2006) reported that apo E polymorphisms were associated with LDL levels and carotid intima-media thickness but were not predictive of incident CAD.^[17]

Sofat (2016) published a meta-analysis of three studies of circulating apo E and CVD events.^[18] The method for selecting the studies was not described. The three studies included 9,587 participants and 1,413 CVD events. In the pooled analysis, there was no association of apo E with CVD events. The unadjusted odds ratio (OR) for CVD events for a standard

deviation increase in apo E concentration was 1.02 (95% CI, 0.96 to 1.09). After adjustment for other cardiovascular risk factors, the OR for CVD for a standard deviation increase in apo E concentration was 0.97 (95% CI 0.82 to 1.15).

A systematic review by Zhao (2017) assessed the link between apo E polymorphisms and premature CAD.^[19] Premature CAD (PAD) was defined as CAD in males below age 55 and females below age 65. The review included 18 research reports with a low to moderate risk of bias, for a total of 2,361 cases of PCAD and 2,811 controls. Overall, the e2 allele was not significantly associated with PCAD. However, when results were stratified by race, the e2 allele appeared to increase the risk of PCAD in Asians (OR 1.54, 95% CI 1.09 to 2.17, as compared to the e3 allele), while a protective effect was seen in Caucasians (OR 0.77, 95% CI, 0.62-0.95, as compared to the e3 allele). Subgroup analysis showed a decreased risk of myocardial infarction associated with e2 compared to e3 (OR 0.70, 95% CI 0.49 to 0.98). Overall, the e4 allele was associated with greater risk of PCAD (OR 1.62, 95% CI 1.27 to 2.06). This increased risk was seen for all racial groups.

An earlier meta-analysis published by Bennet (2007) summarized the evidence from 147 studies on the association of apo E genotypes with lipid levels and cardiac risk.^[20] Eighty-two studies included data on the association of apo E with lipid levels, and 121 studies reported the association with clinical outcomes. The authors reported that patients with the apo e2 allele had LDL levels that were approximately 31% less compared with patients with the apo e4 allele. Patients with the apo e3 allele had an approximately 20% decreased risk for coronary events compared with patients with apo e2 (OR 0.80, 95% CI 0.70 to 0.90), and patients with the apo e4 had an estimated 6% higher risk of coronary events that was not statistically significant (OR 1.06, 95% CI 0.99 to 1.13).

No studies were identified that compared the health outcomes of patient management based on apo E genotypes compared with patient management based on conventional risk assessment measures such as LDL. Therefore, it is unclear how the associations reported above can be used to improve health outcomes over current patient management procedures.

APO E AS A PREDICTOR OF RESPONSE TO THERAPY

ApoE has been investigated as a predictor of response to therapy by examining apo E alleles in the intervention arm(s) of lipid-lowering trials. Some data have suggested that patients with an apo e4 allele may respond better to diet-modification strategies.^[21-23] Other studies have suggested that response to statin therapy may vary with apo E genotype and that the e2 allele indicates greater responsiveness to statins.^[21,23-26]

No studies were identified that directly compared the treatment plans and health outcomes of patient management that was based on apo E status with those based on conventional lipid measures.

PRACTICE GUIDELINE SUMMARY

No clinical practice guidelines or position statements from U.S. professional associations were identified that recommended the use of apo E in cardiovascular risk assessment, including but not limited to the following:

- The 2013 American College of Cardiology/American Heart Association guidelines for the assessment of cardiovascular risk in asymptomatic patients.^[27]

- The 2009 U.S. Preventive Services Task Force (USPSTF) recommendations on the use of nontraditional risk factors for the assessment of coronary heart disease.^[28]
- The American Diabetes Association and the American College of Cardiology Foundation consensus conference publication.^[29]

SUMMARY

APO E AS A PREDICTOR OF CARDIOVASCULAR DISEASE

There is some research that shows that apolipoprotein E (apo E) genotype may have an effect on cholesterol levels and risk for coronary artery disease (CAD). However, there is not enough research to show that testing for apo E genotype helps to improve health outcomes for people at risk for CAD. There are no clinical guidelines based on research that recommend testing apo E genotype for cardiovascular risk. Therefore, the use of apo E measurements in the risk assessment and management of cardiovascular disease is considered investigational.

APO E AS A PREDICTOR OF RESPONSE TO THERAPY

There is not enough research to show that genetic testing of apolipoprotein E (apo E) can improve health outcomes for people that are considering starting a statin medication to reduce their cardiovascular risk. Therefore, apo E testing to predict response to lipid-lowering therapy is considered investigational.

REFERENCES

1. den Dunnen, JT, Dalgleish, R, Maglott, DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. *Human mutation*. 2016 Jun;37(6):564-9. PMID: 26931183
2. TEC Assessment 2002. "C-Reactive Protein as a Cardiac Risk Marker (Special Report)." BlueCross BlueShield Association Technology Evaluation Center, Vol. 17, Tab 23.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001 May 16;285(19):2486-97. PMID: 11368702
4. Koch, W, Hoppmann, P, Schomig, A, Kastrati, A. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. *International journal of cardiology*. 2008 Mar 28;125(1):116-7. PMID: 17433475
5. Kulminski, AM, Ukraintseva, SV, Arbeev, KG, et al. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. *Journal of the American Geriatrics Society*. 2008 Mar;56(3):478-83. PMID: 18179501
6. Schmitz, F, Mevissen, V, Krantz, C, et al. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. *European journal of clinical investigation*. 2007 Feb;37(2):106-8. PMID: 17217375

7. Vaisi-Raygani, A, Rahimi, Z, Nomani, H, Tavailani, H, Pourmotabbed, T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. *Clinical biochemistry*. 2007 Oct;40(15):1150-6. PMID: 17689519
8. Ciftdogan, DY, Coskun, S, Ulman, C, Tikiz, H. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. *Journal of clinical lipidology*. 2012 Jan-Feb;6(1):81-7. PMID: 22264578
9. Vasunilashorn, S, Gleib, DA, Lan, CY, Brookmeyer, R, Weinstein, M, Goldman, N. Apolipoprotein E is associated with blood lipids and inflammation in Taiwanese older adults. *Atherosclerosis*. 2011 Nov;219(1):349-54. PMID: 21840004
10. Davignon, J, Gregg, RE, Sing, CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis*. 1988 Jan-Feb;8(1):1-21. PMID: 3277611
11. Hallman, DM, Boerwinkle, E, Saha, N, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. *American journal of human genetics*. 1991 Aug;49(2):338-49. PMID: 1867194
12. de Andrade, M, Thandi, I, Brown, S, Gotto, A, Jr., Patsch, W, Boerwinkle, E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. *American journal of human genetics*. 1995 Jun;56(6):1379-90. PMID: 7762561
13. Eichner, JE, Kuller, LH, Orchard, TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. *The American journal of cardiology*. 1993 Jan 15;71(2):160-5. PMID: 8421977
14. Wilson, PW, Myers, RH, Larson, MG, Ordovas, JM, Wolf, PA, Schaefer, EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA*. 1994 Dec 7;272(21):1666-71. PMID: 7966894
15. Wilson, PW, Schaefer, EJ, Larson, MG, Ordovas, JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. *Arteriosclerosis, thrombosis, and vascular biology*. 1996 Oct;16(10):1250-5. PMID: 8857921
16. Sharrett, AR, Ballantyne, CM, Coady, SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*. 2001 Sep 4;104(10):1108-13. PMID: 11535564
17. Volcik, KA, Barkley, RA, Hutchinson, RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *American journal of epidemiology*. 2006 Aug 15;164(4):342-8. PMID: 16760224
18. Sofat, R, Cooper, JA, Kumari, M, et al. Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. *PLoS medicine*. 2016 Oct;13(10):e1002146. PMID: 27755538
19. Zhao, QR, Lei, YY, Li, J, Jiang, N, Shi, JP. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a meta-analysis. *Clinical chemistry and laboratory medicine*. 2017 Feb 01;55(2):284-98. PMID: 27394044
20. Bennet, AM, Di Angelantonio, E, Ye, Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *JAMA*. 2007 Sep 19;298(11):1300-11. PMID: 17878422
21. Ordovas, JM, Mooser, V. The APOE locus and the pharmacogenetics of lipid response. *Current opinion in lipidology*. 2002 Apr;13(2):113-7. PMID: 11891412
22. Sarkkinen, E, Korhonen, M, Erkkila, A, Ebeling, T, Uusitupa, M. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and

- dietary cholesterol. *The American journal of clinical nutrition*. 1998 Dec;68(6):1215-22. PMID: 9846849
23. Vossen, CY, Hoffmann, MM, Hahmann, H, Wusten, B, Rothenbacher, D, Brenner, H. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. *Clinical pharmacology and therapeutics*. 2008 Aug;84(2):222-7. PMID: 18388879
 24. Carmena, R, Roederer, G, Mailloux, H, Lussier-Cacan, S, Davignon, J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. *Metabolism: clinical and experimental*. 1993 Jul;42(7):895-901. PMID: 8345800
 25. Chiodini, BD, Franzosi, MG, Barlera, S, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. *European heart journal*. 2007 Aug;28(16):1977-83. PMID: 17567623
 26. Donnelly, LA, Palmer, CN, Whitley, AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. *Pharmacogenetics and genomics*. 2008 Apr;18(4):279-87. PMID: 18334912
 27. Goff, DC, Jr., Lloyd-Jones, DM, Bennett, G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014 Jul 1;63(25 Pt B):2935-59. PMID: 24239921
 28. Helfand, M, Buckley, DI, Freeman, M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Annals of internal medicine*. 2009 Oct 6;151(7):496-507. PMID: 19805772
 29. Brunzell, JD, Davidson, M, Furberg, CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes care*. 2008 Apr;31(4):811-22. PMID: 18375431
 30. BlueCross BlueShield Association Medical Policy Reference Manual "Novel Lipid Risk Factors in Risk Assessment and Management of Cardiovascular Disease." Policy No. 2.04.65

CODES

Codes	Number	Description
CPT	81401	Molecular pathology procedure, Tier 2, Level 2
HCPCS	None	

Date of Origin: January 2013